Syndax Pharmaceuticals Inc (SNDX) Q4 2025 Earnings Call Highlights: Robust Revenue Growth and ... [Yahoo! Finance]
Syndax Pharmaceuticals, Inc. (SNDX)
Last syndax pharmaceuticals, inc. earnings: 3/3 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.syndax.com
Company Research
Source: Yahoo! Finance
This article first appeared on GuruFocus Total Revenue: $172.4 million for 2025. Revuforj Net Revenue: $124.8 million in 2025, with a 38% increase in Q4 compared to Q3. Niktimvo Net Revenue: $151.6 million in 2025, with a 22% increase in Q4 compared to Q3. Collaboration Revenue from Niktimvo: $42.4 million in 2025. Cash, Equivalents, and Marketable Securities: $394 million at the end of 2025. R&D and SG&A Expenses Guidance for 2026: Approximately $400 million, excluding $50 million in non-cash stock compensation expense. Warning! GuruFocus has detected 8 Warning Signs with SNDX. Is SNDX fairly valued? Test your thesis with our free DCF calculator. Release Date: February 26, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript Positive Points Syndax Pharmaceuticals Inc ( NASDAQ:SNDX ) achieved robust financial results in 2025, with total revenue reaching $172 million, driven by successful launches of Revuforj
Show less
Read more
Impact Snapshot
Event Time:
SNDX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SNDX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SNDX alerts
High impacting Syndax Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
SNDX
News
- Syndax Pharmaceuticals (SNDX) was given a new $45.00 price target by Stifel Nicolaus.MarketBeat
- Syndax Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
- Syndax Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateGlobeNewswire
- Syndax Announces Participation in March Investor ConferencesGlobeNewswire
- Syndax to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call and Webcast on February 26, 2026GlobeNewswire
SNDX
Earnings
- 2/26/26 - Miss
SNDX
Sec Filings
- 2/26/26 - Form S-8
- 2/26/26 - Form 10-K
- 2/26/26 - Form 8-K
- SNDX's page on the SEC website